MDS Nordion of Kanata, Ontario, has upgraded its yttrium-90 (Y-90) microsphere administration system for TheraSphere, a targeted internal radiation therapy for patients with inoperable, primary liver cancer.
The disposable tubing and tubing connections have been redesigned to minimize barriers and enhance the fluid pathway, according to the company.
TheraSphere is a low-toxicity therapy, which contains yttrium-90. The product is injected into the main artery of a patient's liver through a catheter, which allows delivery directly to the tumor through blood vessels.
Related Reading
MDS reports decreased revenue in Q4, January 8, 2009
MDS Nordion names Covitz to new post, October 15, 2008
MDS revenues dip in third quarter, September 4, 2008
MDS plans restructuring, July 18, 2008
MDS sues AECL for $1.6 billion over Maple reactors, July 9, 2008
Copyright © 2009 AuntMinnie.com
